Fused cell line and method of obtaining the same
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 11, 2000
Grant Date -
N/A
app pub date -
Dec 31, 1997
filing date -
Oct 22, 1997
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Provided are a human immunocompetent fused cell line, characterized in that any one of a mutant cell selected from the group consisting of ICLU-B, ICLU-T and ICLU-E is used as a parent cell line, wherein said mutant cell is obtained by selecting an 8-azaguanine- or 6-thioguanine-resistant clone from a human Burkitt lymphoma cell line Raji, a human T-cell lymphocytic leukemia cell line PEER and a human eosinophilic leukemia cell line EoL-1, and then treating said clone in order to capable of serum-free culture, and a method of obtaining said human immunocompetent fused cell line. The human immunocoipetent fused cell line obtained by the present invention is used to investigate food functions, novel drugs and production thereof with the view to the elucidation of mechanisms of phenomena of an immune system such as allergies, cancers and the like using human cell lines, and the prevention, diagnosis and therapy of these diseases.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully